Congressman Scott Peters (D-CA) joined Incubate Executive Director John Stanford on the Making Medicine podcast for a wide-ranging conversation on U.S.-China biotech competition, drug pricing policy, and the future of American competitiveness. Representing San Diego -- one of the world's leading biotech hubs -- Peters offered a candid look at the intersection of healthcare policy, biotech industry, venture investment, and national security, and biotech industry. China is no l

In a recent opinion piece, Incubate Executive Director John Stanford and Senator Thom Tillis (R-NC) took to the pages of Fortune with a clear warning: America’s leadership in life sciences innovation is not guaranteed. Policies that undermine intellectual property protections, distort market incentives, or inject uncertainty into the biotech ecosystem risk driving investment -- and the next generation of cures -- overseas. As global competitors aggressively court biotech cap

Senator Todd Young (R-IN) joined Incubate Executive Director John Stanford on the Making Medicine podcast this week for a wide-ranging conversation on how biotechnology is shaping national security, economic competitiveness, and U.S.-China competition. As Chair of the National Security Commission on Emerging Biotechnology, Young made it clear that the stakes go far beyond healthcare. Biotech is a national security imperative. Biotechnology is central to U.S. supply chains, de

WASHINGTON (April 21) -- Today, Incubate, in partnership with Manatt Health, released new insights from interviews with leading biopharmaceutical investors showing that instability at the Food and Drug Administration (FDA) is increasingly shaping investment decisions. In short, investors aren't just evaluating science -- they're reassessing whether the U.S. regulatory environment is predictable enough to support it. Based on interviews with 16 investors spanning seed, vent